Search

Displaying results 6451 - 6460 of 9702 in total
  1. Drug

    Glembatumumab vedotin

    go.drugbank.com/drugs/DB05996
    Investigational

    A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  2. Drug

    AMG-222

    go.drugbank.com/drugs/DB06011
    Experimental

  3. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    The drug is composed of an IL-6–binding trimer and a IgG-binding domain.

  4. Drug

    TC-2216

    go.drugbank.com/drugs/DB06044
    Investigational

    TC-2216 is an investigational novel small molecule that is being developed as an oral treatment for depression and anxiety disorders. TC-2216 showed greater potency than and anti-depressant effects comparable to selective serotonin reupt...

  5. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. … Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression

  6. Drug

    ICA-105665

    go.drugbank.com/drugs/DB06089
    Investigational

    It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. … ICA-105665 is a novel small molecule compound for the treatment of epilepsy.

  7. Drug

    ISIS 325568

    go.drugbank.com/drugs/DB06099
    Investigational

    ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR).

  8. Drug

    VX-148

    go.drugbank.com/drugs/DB06103
    Experimental

    The IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes. VX-148 is a developed for the treatment of autoimmune diseases. … VX-148 is a second-generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH).

  9. Drug

    AIT-034

    go.drugbank.com/drugs/DB06106
    Experimental

    There is some evidence that AIT-034 could complement Neotrofin as a treatment for Alzheimer's disease and dementia. … AIT-034 is a distinct chemical analog of hypoxanthine and pyrollidone that has been demonstrated in animal studies to enhance memory and to reverse memory deficits in severely impaired animals that do

  10. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector